BVF Inc. IL Grows Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

BVF Inc. IL lifted its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 32.7% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,388,064 shares of the company's stock after purchasing an additional 342,064 shares during the quarter. Axsome Therapeutics accounts for approximately 4.0% of BVF Inc. IL's holdings, making the stock its 4th largest position. BVF Inc. IL owned approximately 2.86% of Axsome Therapeutics worth $117,444,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of AXSM. Pitcairn Co. raised its stake in shares of Axsome Therapeutics by 3.4% in the 4th quarter. Pitcairn Co. now owns 4,562 shares of the company's stock worth $386,000 after buying an additional 148 shares in the last quarter. Meridian Wealth Management LLC raised its position in Axsome Therapeutics by 0.7% in the fourth quarter. Meridian Wealth Management LLC now owns 21,171 shares of the company's stock worth $1,791,000 after acquiring an additional 150 shares in the last quarter. Summit Investment Advisors Inc. lifted its holdings in Axsome Therapeutics by 4.4% in the 4th quarter. Summit Investment Advisors Inc. now owns 3,852 shares of the company's stock valued at $326,000 after acquiring an additional 162 shares during the last quarter. Arizona State Retirement System lifted its holdings in Axsome Therapeutics by 1.8% in the 4th quarter. Arizona State Retirement System now owns 9,054 shares of the company's stock valued at $766,000 after acquiring an additional 164 shares during the last quarter. Finally, Intrust Bank NA grew its stake in shares of Axsome Therapeutics by 6.9% in the 4th quarter. Intrust Bank NA now owns 2,823 shares of the company's stock worth $239,000 after purchasing an additional 183 shares during the last quarter. 81.49% of the stock is owned by institutional investors and hedge funds.

Axsome Therapeutics Stock Down 3.7 %

AXSM stock traded down $4.33 during midday trading on Tuesday, reaching $112.16. The company had a trading volume of 716,105 shares, compared to its average volume of 685,724. The company has a 50 day moving average of $113.06 and a two-hundred day moving average of $104.23. The company has a market capitalization of $5.52 billion, a P/E ratio of -18.72 and a beta of 0.46. Axsome Therapeutics, Inc. has a 1 year low of $64.11 and a 1 year high of $139.13. The company has a current ratio of 2.11, a quick ratio of 2.04 and a debt-to-equity ratio of 3.22.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last announced its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The business had revenue of $118.77 million during the quarter, compared to analyst estimates of $117.83 million. On average, equities research analysts expect that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have issued reports on AXSM shares. Wells Fargo & Company reaffirmed an "overweight" rating and issued a $165.00 price target (up previously from $160.00) on shares of Axsome Therapeutics in a report on Tuesday. Jefferies Financial Group assumed coverage on Axsome Therapeutics in a research report on Monday, April 7th. They set a "buy" rating and a $200.00 target price on the stock. Morgan Stanley increased their price target on Axsome Therapeutics from $125.00 to $190.00 and gave the company an "overweight" rating in a research report on Thursday, February 27th. Bank of America boosted their price objective on Axsome Therapeutics from $143.00 to $167.00 and gave the stock a "buy" rating in a report on Tuesday, February 11th. Finally, Leerink Partners raised their target price on shares of Axsome Therapeutics from $110.00 to $150.00 and gave the stock an "outperform" rating in a report on Monday, February 10th. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $170.33.

Insider Buying and Selling

In other news, CFO Nick Pizzie sold 3,000 shares of the firm's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $131.07, for a total transaction of $393,210.00. Following the transaction, the chief financial officer now owns 42,187 shares in the company, valued at approximately $5,529,450.09. This trade represents a 6.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 22.40% of the stock is currently owned by corporate insiders.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.